Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference

Rhea-AI Summary

Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage therapeutics developer, announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event on December 15, 2020, at 10:40 a.m. EST. The event will be available via live webcast.

The company focuses on unmet medical needs in neurotology, rhinology, and CNS disorders, with products like AM-125 for vertigo and AM-111 for acute inner ear hearing loss under development. Auris Medical, founded in 2003, is headquartered in Hamilton, Bermuda, with operations in Basel, Switzerland.

News Market Reaction – EARS

+10.51%

+10.51% Session move

In the trading session that priced this news, EARS gained 10.51%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the 13th Annual LD Micro Main Event investor conference on Tuesday, December 15, 2020, at 10:40 a.m. EST. The event will be webcast live and available via the event homepage https://ve.mysequire.com/.

About Auris Medical

Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders. The Company is focused on the development of intranasal betahistine for the treatment of vertigo (AM-125, in Phase 2) and for the prevention of antipsychotic-induced weight gain and somnolence (AM-201, post Phase 1b). Through its affiliate Altamira Medica, the Company is developing a nasal spray for protection against airborne pathogens and allergens (AM-301). In addition, Auris Medical has two Phase 3 programs under development: Sonsuvi® (AM-111) for acute inner ear hearing loss and Keyzilen® (AM-101) for acute inner ear tinnitus. The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Auris Medical Holding Ltd. trade on the NASDAQ Capital Market under the symbol “EARS.”

Investor contact:

investors@aurismedical.com     

FAQ

When is Thomas Meyer presenting for Auris Medical (EARS)?

Thomas Meyer will present at the LD Micro Main Event on December 15, 2020, at 10:40 a.m. EST.

Where can I watch the Auris Medical (EARS) presentation live?

The presentation will be webcast live on the event homepage.

What is Auris Medical’s focus in drug development?

Auris Medical develops therapeutics for neurotology, rhinology, allergy, and CNS disorders.

What products are in development by Auris Medical (EARS)?

Auris Medical is developing AM-125 for vertigo, AM-201 for antipsychotic-related effects, and AM-111 for acute inner ear hearing loss.

What is the stock symbol for Auris Medical?

Auris Medical trades on NASDAQ under the symbol EARS.